Last updated on November 2019

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome


Brief description of study

This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes mellitus/impaired glucose tolerance and/or uncontrolled hypertension

Detailed Study Description

This Phase 3 study involves two phases, an open-label (OL) phase and a randomized-withdrawal (RW) phase. Patients will dose-escalate in 100 mg increments to a target dose of 400 mg orally once daily during the open-label phase. Patients will remain on open-label treatment until week 22 at which time they will be evaluated for the randomized-withdrawal phase based on pre-defined hyperglycemia and hypertension response criteria. Eligible patients will then be randomized to receive either relacorilant or placebo at a 1:1 ratio for 12 weeks. Patients who do not meet the criteria for randomization will end treatment and may be eligible to roll over into an extension safety study. Patients who complete the randomized-withdrawal phase of the study may also be eligible to roll over into an extension study.

Clinical Study Identifier: NCT03697109

Find a site near you

Start Over

Site 2

Metairie, LA United States
  Connect »

Site 9

Aurora, CO United States
  Connect »

Site 10

Miami, FL United States
  Connect »

Site 7

Indianapolis, IN United States
  Connect »

Site 4

Jackson, MS United States
  Connect »

Site 8

Albany, NY United States
  Connect »

Site 6

Jamaica, NY United States
  Connect »

Site 1

Wilmington, NC United States
  Connect »

Site 11

Oklahoma City, OK United States
  Connect »

Site 5

Summerville, SC United States
  Connect »

Site 3

El Paso, TX United States
  Connect »

Site 14

Atlanta, GA United States
  Connect »

Site 13

Saint Louis, MO United States
  Connect »

Site 12

Napoli, Italy
  Connect »

Site 17

Columbus, OH United States
  Connect »

Site 18

Houston, TX United States
  Connect »

Site 15

Messina, Italy
  Connect »

Site 21

Phoenix, AZ United States
  Connect »

Site 20

Ann Arbor, MI United States
  Connect »

Site 19

Pittsburgh, PA United States
  Connect »

Site 25

Girona, Spain
  Connect »

Site 24

Madrid, Spain
  Connect »

Site 22

Málaga, Spain
  Connect »

Site 23

Sevilla, Spain
  Connect »

Site 22

Málaga, Spain
  Connect »

Site 27

Sofia, Bulgaria
  Connect »

Site 29

Kfar Saba, Israel
  Connect »

Site 28

Petach Tikva, Israel
  Connect »

Site 26

Milano, Italy
  Connect »

Site 22

Málaga, Spain
  Connect »

Site 22

Málaga, Spain
  Connect »

Site 36

Los Angeles, CA United States
  Connect »

Site 42

Santa Monica, CA United States
  Connect »

Site 32

Washington, WA United States
  Connect »

Site 41

Chicago, IL United States
  Connect »

Site 39

New York, NY United States
  Connect »

Site 35

New York, NY United States
  Connect »

Site 31

Everett, WA United States
  Connect »

Site 30

Jerusalem, Israel
  Connect »

Site 43

Ancona, Italy
  Connect »

Site 38

Turin, Italy
  Connect »

Site 34

Rotterdam, Netherlands
  Connect »

Site 37

Chrzanów, Poland
  Connect »

Site 33

Lublin, Poland
  Connect »

Site 22

Málaga, Spain
  Connect »